We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CrowdStrike (CRWD) Beats, Snowflake (SNOW) Mixed in Q3
Read MoreHide Full Article
Markets were tepid on this Hump Day, after fair-to-middling private-sector employment numbers from ADP (ADP - Free Report) ahead of today’s opening bell, and an announcement mid-day that New York state is scheduled to receive 170K vaccine doses by December 15th — two weeks from yesterday. The biggest performing major index on the day was the Dow, +0.20%, followed by the 28th all-time high close from the S&P 500, +0.18%. The small-cap Russell 2000 brought in +0.11% on the day, while the Nasdaq finished narrowly in the red, -0.05%.
High-risk healthcare workers and senior living facility tenants will represent the first tier of Covid-19 vaccinations from Pfizer (PFE - Free Report) -BioNTech (BNTX - Free Report) , followed by the general elderly population — much in line with Great Britain’s approval of the Pfizer-BioNTech vaccine made earlier in the day. But the market had already been pricing in a post-Covid world; apparently investors are keeping something of a wet blanket on current valuations.
The rollout of Covid-19 vaccines promises to be extraodinarily huge and complex. That there is some sort of dosages plan is a big step in the right direction, but there are always pitfalls — and they’re not always visible to the naked eye in real time. But Operation Warp Speed has had its shingle up for several months now; we look for the operation’s execution to adhere to military-like precision. In other words, the outlook for the vaccine rollout looks to be a huge challenge, but those in charge appear prepared.
Cyberintelligence security firm CrowdStrike (CRWD - Free Report) surged well ahead of estimates on every metric in its Q3 report this afternoon, with 8 cents per share reported easily surpassing the $0.00 expected. Revenues of $232 million topped the expected outpaced the $213.7 million analysts were anticipating, and rose 86% year over year. Revenues for fiscal Q4 are now expected in a range of $245.5 million - 250.5 million, notably ahead of the $231 million in the most recent Zacks consensus.
Shares of CrowdStrike are up 11% on the news, putting the stock performance at roughly +110% year to date. We look for analysts covering the company — which has not missed an earnings estimate since its IPO in 2018 — to ratchet up estimates, and perhaps pull a higher Zacks Rank as a result.
The debut earnings report release from enterprise software fledgling Snowflake (SNOW - Free Report) was a rather inauspicious one: a bottom line of -$1.01 per share was well off the pace of -27 cents per share in the Zacks consensus; then again, initial public earnings reports are notoriously hard to gauge. Revenues beat expectations slightly: $148.5 million topped the $146.9 million estimate, +11.5% year over year. Yet shares are selling on the news 4.5%; recall Snowflake’s IPO surged right out of the gate. This looks to be a sell-the-news move.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Shutterstock
CrowdStrike (CRWD) Beats, Snowflake (SNOW) Mixed in Q3
Markets were tepid on this Hump Day, after fair-to-middling private-sector employment numbers from ADP (ADP - Free Report) ahead of today’s opening bell, and an announcement mid-day that New York state is scheduled to receive 170K vaccine doses by December 15th — two weeks from yesterday. The biggest performing major index on the day was the Dow, +0.20%, followed by the 28th all-time high close from the S&P 500, +0.18%. The small-cap Russell 2000 brought in +0.11% on the day, while the Nasdaq finished narrowly in the red, -0.05%.
High-risk healthcare workers and senior living facility tenants will represent the first tier of Covid-19 vaccinations from Pfizer (PFE - Free Report) -BioNTech (BNTX - Free Report) , followed by the general elderly population — much in line with Great Britain’s approval of the Pfizer-BioNTech vaccine made earlier in the day. But the market had already been pricing in a post-Covid world; apparently investors are keeping something of a wet blanket on current valuations.
The rollout of Covid-19 vaccines promises to be extraodinarily huge and complex. That there is some sort of dosages plan is a big step in the right direction, but there are always pitfalls — and they’re not always visible to the naked eye in real time. But Operation Warp Speed has had its shingle up for several months now; we look for the operation’s execution to adhere to military-like precision. In other words, the outlook for the vaccine rollout looks to be a huge challenge, but those in charge appear prepared.
Cyberintelligence security firm CrowdStrike (CRWD - Free Report) surged well ahead of estimates on every metric in its Q3 report this afternoon, with 8 cents per share reported easily surpassing the $0.00 expected. Revenues of $232 million topped the expected outpaced the $213.7 million analysts were anticipating, and rose 86% year over year. Revenues for fiscal Q4 are now expected in a range of $245.5 million - 250.5 million, notably ahead of the $231 million in the most recent Zacks consensus.
Shares of CrowdStrike are up 11% on the news, putting the stock performance at roughly +110% year to date. We look for analysts covering the company — which has not missed an earnings estimate since its IPO in 2018 — to ratchet up estimates, and perhaps pull a higher Zacks Rank as a result.
The debut earnings report release from enterprise software fledgling Snowflake (SNOW - Free Report) was a rather inauspicious one: a bottom line of -$1.01 per share was well off the pace of -27 cents per share in the Zacks consensus; then again, initial public earnings reports are notoriously hard to gauge. Revenues beat expectations slightly: $148.5 million topped the $146.9 million estimate, +11.5% year over year. Yet shares are selling on the news 4.5%; recall Snowflake’s IPO surged right out of the gate. This looks to be a sell-the-news move.
Questions or comments about this article and/or its author? Click here>>
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>